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Background: It is well known that illicit use of methadone and buprenorphine is common among people with an
opioid dependence. Less notice has been taken of the fact that these substances are also used for extended
periods of self-treatment, as a way of handling barriers to OST. In this study, motives for self-treatment are investigated,
as well as attitudes and perceived barriers to OST among drug users with an opioid dependence in Sweden.
Method: The study is based on qualitative research interviews with 27 opioid users who have treated themselves with
methadone or buprenorphine for a period of at least three months.
Results: The duration of self-treatment among the interviewees varied from 5 months to 7 years. Self-treatment often
began as a result of a wish to change their life situation or to cut back on heroin, in conjunction with perceived barriers
to OST. These barriers consisted of (1) difficulties in gaining access to OST due to strict inclusion criteria, limited access
to treatment or a bureaucratic and arduous assessment process, (2) difficulties remaining in treatment, and (3) ambivalence
toward or reluctance to seek OST, primarily due to a fear of stigmatization or disciplinary action. Self-treatment was
described as an attractive alternative to OST, as a stepping stone to OST, and as a way of handling waiting lists, or as a
saving resource in case of involuntary discharge.
Conclusion: Illicit use of methadone and buprenorphine involve risks but may also have important roles to play for users
who are unwilling or not given the opportunity to enter OST. A restrictive and strict rehabilitation-oriented treatment model
may force many to manage their own treatment. More generous inclusion criteria, a less complex admission process, fewer
involuntary discharges, and less paternalistic treatment may lead to increasing numbers seeking OST. Control measures are
necessary to prevent diversion and harmful drug use but must be designed in such a way that they impose as few
restrictions as possible on the daily life of patients.
Keywords: Illicit use, Heroin, Methadone, Buprenorphine, Self-treatment, Opioid substitution treatment, Barriers to
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Introduction and aim
Methadone- or buprenorphine-based opioid substitution
treatment (OST) is a well-established treatment with posi-
tive effects on mortality, social and health problems, and
criminality among people with an opioid dependence [1-3].
However, the medications used in the treatment also have a
high abuse potential and are sought after on the illicit
drugs market [4,5]. In several countries, diversion—the* Correspondence: torkel.richert@mah.se
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article, unless otherwise stated.selling or sharing of medication—has been highlighted as
a serious problem, with reference to (among other things)
methadone-related deaths outside the treatment [6-10].
Illicit use of methadone and buprenorphine may bring
health-related and legal issues but may also bring certain
advantages. According to a study by Harris and Rhodes
[11], illicit methadone use may serve as a ‘protection
strategy’ enabling people with a drug dependence to
control their drug use, improve their social relations,
and protect themselves against hepatitis C. Illicit use of
buprenorphine can also reduce health risks and improve
quality of life compared to heroin use [5,12].Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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by people with an established opioid dependence, often
for various therapeutic purposes: to avoid withdrawal
symptoms, for self-detoxification, to avoid heroin use, or
as an analgesic [13-15].
Prevalence levels, user populations, and motives for
using the substances vary from country to country. This
may be explained by the differences in access to heroin
and other opioids and by the differentiated pricing levels
for various substances but also by the access to and the
design of OST [5,16]. Some studies have pinpointed bar-
riers to OST as an important explanation as to why users
are self-medicating with methadone or buprenorphine.
Such barriers may be associated with difficulties in gain-
ing access to treatment [17,18] or with issues such as
the treatment services not attracting or retaining opioid-
dependent people to a sufficient degree [19-21].
Little is known about why opioid-dependent people re-
frain from seeking OST, how they perceive and handle
existing barriers, as well as the significance of illicit use
of methadone or buprenorphine in this context. The aim
of this study is to investigate attitudes and perceived bar-
riers to OST, the various motives for self-treatment, and
the functions which self-treatment may serve for opioid-
dependent people in Sweden.
The study is based on qualitative interviews with
people with experience of self-treatment using metha-
done or buprenorphine for an extended period. We
define ‘long-term self-treatment’ (henceforth ‘self-treat-
ment’) as a daily or near-daily illicit use of one of the
substances for a continuous period of at least 3 months.
Opioid substitution treatment in Sweden
The Swedish OST model has been described as restrict-
ive and rehabilitation oriented. The inclusion criteria are
strict, treatment is often highly structured and con-
trolled, and the dosage levels are relatively high. OST
may only be administered by specialist psychiatric
healthcare. Retention levels are typically high, and treat-
ment has a clear focus on abstinence from drugs, re-
habilitation, and lifestyle change [22-25].
Two circumstances in particular have had a great im-
pact on the development of the Swedish OST model.
Firstly, for a long time, there existed a vehement ideo-
logical resistance to OST in Sweden. This resistance re-
sulted in a limited access to treatment, rigorous
inclusion criteria, in addition to strict regulations and
controls while in treatment [25-27]. Secondly, healthcare
and social services in Sweden have joint mandatorship
of the addiction treatment system. This has led to a clear
separation of social and medical interventions, while
simultaneously laying great stress on the importance of
cooperation. For service providers in Swedish OST, the
treatment’s legitimacy rests on factors such astherapeutic intervention; in doing more than just redu-
cing harm. The general view is that OST should be
aimed at social rehabilitation and ‘normalization,’ which
means living a life ‘like most people do,’ free from drug
abuse and integrated in mainstream society [25,28].
National regulations are issued by Socialstyrelsen (The
Swedish National Board of Health and Welfare). The
rules are strict and exclude populations which would
have been offered OST in many other countries. The
current regulations [29] have been in force since 2010
and stipulate that OST may only be given to people over
the age of 20 with at least 1 year’s documented opiate
(heroin, morphine, or opium) dependence. Users who
primarily are dependent on other opioids, such as bupre-
norphine, fentanyl, or methadone, may not be offered
OST. Nor may treatment be offered to users who are
poly-dependent on other narcotic substances or alcohol,
which pose a ‘substantial medical risk’. Medication is
supposed to be administered under daily supervision for
the first 6 months or for longer if deemed necessary.
Regular urine tests are taken to check that no prohibited
substances are used.
The regulations also outline a number of circumstances
when treatment should be suspended: if the patient is
absent from treatment for more than 1 week, repeatedly
relapses into illicit drug use, uses alcohol in a way which
constitutes a medical risk, manipulates his/her urine
samples, or if he/she is convicted of drug offenses. If a
patient is discharged, a 3-month suspension period is initi-
ated, during which he/she is barred from seeking re-
admission to OST.
The current regulations are a result of a gradual move-
ment toward a less restrictive treatment policy over the
last decade. Prior to 2005 at least 4 years of documented
intravenous opiate addiction, in addition to three failed
attempts—documented in medical records—at drug-free
treatment were required in order to qualify for OST.
Prior to 2010, collaboration between healthcare and so-
cial services was mandatory—anyone who applied for
OST was expected to have a treatment plan in place
with the social services. The suspension period in the
event of involuntary discharged was two years in the
1990s but was reduced to 6 months in 2005 and further
lowered to 3 months in 2010 [30].
Prior to 2005, access to OST was strictly limited, lead-
ing to long waiting lists, often several years [31]. After
the new regulations [32] were issued, however, access to
treatment increased rapidly. On a regional level, the
changes toward a less restrictive model have continued
since the introduction of the 2010 regulations. Involun-
tary discharges have become less frequent, particularly
in Stockholm and Scania, where the majority of the
Swedish patients are to be found (ongoing review by
Socialstyrelsen).
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inclusive, substantial numbers of opioid-dependent users
remain outside the treatment system against their will,
mainly as a result of the rules banning specific opiates,
the exclusion criteria, and the suspension period. In
addition to this, some healthcare regions have long wait-
ing lists and a protracted and arduous admission
processa.Methods
Participants and recruitment
The interviewees in this study were recruited as part of
a comprehensive research project about diversion and
illicit use of methadone and buprenorphine in Sweden.
In this project, structured interviews were conducted
with 411 OST patients in five towns and cities in the
South of Sweden—the locations were selected in order
to cover a variety of local drug scenes and varying access
to OST—and with 98 opioid users at the Malmö needle
exchange.
Posters and scheduling lists were put up at the various
sites. We then spent from two to ten workdays at each
OST program and several weeks at the needle exchange,
carrying out scheduled interviews and recruiting add-
itional participants among the visitors. A more in-depth
description of the participants and recruitment process
can be found in one of our previous articles [33].
One part of the interview dealt with experiences of
methadone or buprenorphine use outside treatment and
covered the procurement of the substances, manner of
intake, as well as the extent and the motives for the
usage. We soon discovered that it was common among
the interviewees to have used one or other of the sub-
stances illicitly for an extended period—sometimes for
years—as a means of self-treatment. This gave us the
idea of conducting a specific study of the phenomenon.
In the quantitative study, 32% of the interviewees
stated self-treatment as their primary motive for illicit
use. Of them, around 30 people were offered the
opportunity to participate in an in-depth qualitative
interview. The objective was to create a broad and
varied study population in terms of factors such as
gender, age, history of drug use, and life situation. Fur-
thermore, we wanted the population to include both
users with a current self-treatment and patients
enrolled in OST, who previously had managed treat-
ment on their own. A total of 27 people agreed to
participate in the study. All of them met the following
inclusion criteria: (1) current or previous illicit drug
use, primarily opioid-based, (2) experience of self-
treatment with methadone or buprenorphine for a
continuous period of at least 3 months, and (3) at least
20 years of age.Procedure
The interviews were carried out by Johnson and Richert.
Before the interviews began, we informed all inter-
viewees verbally and in writing about the project and its
aims. We explained that the study was completely confi-
dential and independent from the treatment programs,
that participation would not affect their individual treat-
ment, and that they had the option of ending the inter-
view at any time.
The in-depth interviews were normally conducted fol-
lowing on directly from the structured interview, but in
some cases we scheduled a new interview. Several inter-
views took place in a separate room at the OST clinics
or in an interview room at the needle exchange. Some
interviews were conducted in the home or workplace of
the interviewee.
The interviews were topic based, but the interviewees
were given ample opportunity to talk freely. The topics
covered issues such as current life situation, experiences
of drug use, previous treatment experiences, as well as
experiences of using methadone and buprenorphine out-
side treatment. Particular attention was paid to the mo-
tives for self-treatment, attitudes to OST, and perceived
barriers to OST.
All the participants in the study were offered a gift
voucher worth SEK 200 (approximately EUR 22) or a
book, regardless of whether they completed the inter-
view or not. The interviews lasted between 30 and
90 min, and in a couple of cases supplementary inter-
views were conducted. A total of 11 interviews were re-
corded and transcribed verbatim. During the remaining
16 interviews, where the interviewees asked not to be re-
corded, we took notes which were typed up afterwards.Analysis
The analysis was performed as a manual, three-step
qualitative textual analysis. First, we did a close reading
of the material and performed a summary coding based
on the overarching themes in the interview guide. Then,
we made a second more detailed coding, where we iden-
tified similarities and differences in relation to the ori-
ginal themes. Finally, we went through the material one
last time in order to identify suitable illustrative and rep-
resentative quotes.Ethics
As already noted, the study forms part of a larger re-
search project into diversion and non-medical use of
methadone and buprenorphine in Sweden. The project
was conducted in accordance with The Swedish Ethical
Review Act (SFS 2004:460). The design and execution of
the project was approved by the Regional Ethical Review
Board at Lund University. All names used in this article
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Results
Sample characteristics and pathways to self-treatment
Twenty males and seven females, aged between 24 and
53 years, participated in the study. All of them were ex-
perienced drug users with at least 4 years of regular opi-
oid use. Heroin had been the primary drug for 24
interviewees, while the other three had mainly used
other opioids. All had also used several other types of
substances.
At the time of the interview, 13 people had a current
self-treatment. The remaining 14 were admitted to OST,
meaning that their self-treatment dated back some time.
A total of 20 people had some experience of OST. The
duration of the self-treatment varied between 5 months
and 7 years, but in the majority of cases it had lasted
between 1 and 2 years. A total of 13 patients had pri-
marily used buprenorphine, and 14 mainly methadone,
although nearly all had experience of both substances.
There was considerable variation within the group in
terms of life situation, as well as extent and conse-
quences of drug use. Some described very severe drug
problems and a life situation characterized by housing
problems, support strategies based on crime, and
marginalization. Others described how they, despite drug
use leading to physical dependence, had been able to
lead a relatively well-structured life with stable housing
and work. In some cases, their drug use had been hidden
from family, friends, and colleagues.
The interviewees described a number of pathways into
self-treatment. All had first come across methadone or
buprenorphine outside treatment, often as a means of
alleviating heroin withdrawal symptoms, for self-
detoxification purposes, or as a result of being unable to
get hold of heroin. Often, first-occasion use was of short
duration, a few days to a week.
More extended self-treatment was initiated at a later
stage. For nearly everyone this had happened at a point
when they were trying to quit or cut back on heroin use,
in order to change their life situation. The impetus for
change often was the culmination of a number of nega-
tive consequences of the drug use. In other cases, it had
come in connection with a positive life event, such as
starting a new relationship, becoming a parent, or an
offer of employment. The transition to methadone or
buprenorphine nearly always resulted in a reduction in
heroin use and an improved life situation. In particular,
the reduced outlays for drugs, as well as the long action
of the substances, were seen as great advantages.
The interviewees described various attitudes to OST
and different reasons as to why they managed treatment
on their own. Three major explanations for self-treatment emerged: (1) difficulties in getting access to
OST, (2) difficulties in remaining in OST, and (3) am-
bivalence about or reluctance to enter OST.
Difficulties in gaining access to OST
To qualify and prove that you are a ‘genuine addict’
Having been denied OST was a common motive for
starting self-treatment. Several interviewees described
how their application for OST had been rejected since
they did not fulfil the inclusion criterion of 1 year’s
(alternatively 4 years’) documented opiate dependence.
Some of the interviewees had hidden their drug use
from friends, family, and colleagues and lacked docu-
mentation in the form of contacts with healthcare,
dependence treatment, social services, or the police.
Others were denied treatment since they were primarily
dependent on synthetic opioids rather than opiates,
which as previously noted is a requirement to get access
to OST in Sweden. Other reasons for applications being
rejected were excessive polydrug use (often in the form
of sedatives), an unclear residence situation, or an
impending prison sentence. Some explained that they
did not even get to the stage where they could submit a
formal application to the addiction treatment services,
since they were dissuaded or prevented from applying by
another authorityb.
One example is Hamza, a young man aged about 25,
who at the time of our interview recently had been
admitted to OST for the first time. Hamza started using
drugs and pills in his early teens and had been
dependent on benzodiazepines and various analgesics, in
particular oxycodone, for several years. He had also used
heroin on and off. Hamza described how he previously
had had a very difficult life situation characterized by
mental ill health, uncertain residence situation, and an
extensive polydrug use which resulted in several over-
doses. In recent years, he had managed to improve his
social situation by treating himself with methadone,
which he bought from patients in OST. Asked why he
had not applied for OST earlier, he replied:
I’ve been thinking about it for years. But I haven’t been
admitted before. I didn’t have enough documented
opioid abuse. They [the addiction treatment services]
want it clearly to show that you’re addicted to heroin,
which I’ve never been […] The first time I suggested
substitution treatment to the social services, they just
snorted derisively. They said that wasn’t for me, you’re
not a junkie, you’re a polydrug user. They forced me
into compulsory treatment […] There’s hardly anything
about heroin in my records, but I’ve had several serious
methadone ODs, which was probably the reason why I
was finally admitted to treatment. They’ve started to
relax the strict regulations a bit in recent years.
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‘border guard’ to OST. Since he applied for treatment
before 2010, he had to go via the social services. The
example also shows how the addiction treatment ser-
vices initially denied him treatment because he lacked
‘proper’ documentation, only to admit him at a later
stage, thus ignoring the criterion of admitting only
people with a documented opioid dependence. Presum-
ably, this was motivated by the fact that Hamza had
overdosed on several occasions. The example indicates
that, in the meeting between an applicant and official,
there exists a certain amount of leeway when applying
the regulations.
Another interviewee who encountered obstacles to
OST is Peter, a man in his 40s, who has self-medicated
with methadone for the last few years. Peter previously
had a long-standing heroin dependence, although hidden
from colleagues, friends, and family. He had had a rela-
tively well-structured life with permanent residence and
work and had never been in treatment. Already at an
early stage of his heroin dependence, Peter had been
motivated to enter OST, but when he was told by the so-
cial services that he had to present extensive documen-
tation proving that he was a heroin addict, he let the
idea go. Instead, he bought methadone illicitly.
I mean, I remember when I was fairly new to heroin,
that I asked about substitution treatment and stuff.
Yeah, are you an injecting drug user, that sort of
thing? Well, I mainly smoke heroin, and I’ve been
doing it for more than a year. Right, so you haven’t
got any needle marks, then? No, no. Have you ever
been arrested by the police or something like that?
No, no. Okay, not been caught shoplifting or
something? I respond ‘No, no.’ So, you can’t prove
that you’re an addict? Then I’m sorry, we can’t offer
you treatment. And that was about five years ago or
so. So, I said, how am I going to get treatment then,
you know? Do I have to commit a crime or something
to get treatment?
Peter described how he had to prove that he was a
‘hard-core addict’ in order to get access to treatment,
which in this case meant exhibiting needle marks or
documentation proving a criminal record. Whether he
fulfilled the criteria for opioid dependency was not even
discussed. This example indicates that the attitudes of
professionals and their norms as to who belongs to the
‘right category’ of drug user may influence an applicant’s
chances of being admitted to OST.
Limited access to OST and an arduous admission process
Even people who fulfil all formal criteria for OST may
encounter difficulties in getting access to treatment.Several interviewees, in particular those who had sought
help some years back, pointed out that long waiting lists
had meant that they were forced to wait a year or more
for treatment. Some described the assessment process as
so drawn-out, complex, and demanding that they had
felt the need to initiate their own treatment.
Marc is a young man who, at the time of the interview,
recently had been admitted to OST, after a second,
drawn-out assessment. In total, he had waited more than
2 years. Most of this time, he had been using illicit
methadone or buprenorphine for self-treatment pur-
poses. The first time he sought help, he gave up after
more than a year on the waiting list and instead started
buying buprenorphine from acquaintances in OST.
I thought it all took too long. Everything took several
months. I mean, it took three months just to get this
appointment (the first information meeting), and then
it took another three months before I saw the doctor,
I hadn’t even given a urine sample, you know, so I
was thinking like, how long is it gonna take? Shit, I’ll
die before I… I was up there nagging them, I called
and talked to them and so on, and they were like ‘yes,
but that’s all we can do right now’ and stuff, and ‘it’ll
take the time it takes’.
Eva had a similar tale to tell. She was 26 years old and
had been in OST for 3 months when we interviewed
her. Prior to this, she had used illicit methadone and
buprenorphine for nearly 4 years, both as part of poly-
drug use and as a means of getting out of a longstanding
heroin addiction. She found the road to OST difficult
and exhausting.
I wanted treatment when I started using
buprenorphinec on my own, but I just didn’t get
around to it. I was too deep in the shit, it was too
chaotic […] After a while, I sought treatment anyway,
but it was so messy,’ coz I was taking loads of benzo,
heroin and speed, and I’ve got ADHD as well, it was
insane. I missed appointments, and couldn’t get a
grip. So, I started self-medicating with buprenorphine,
tried to get off heroin, and to quit benzo and speed.
About six months after I’d started with buprenorhine
I managed to get enough structure and harmony to be
able to seek treatment again. After that it took six
months before I was admitted to treatment, and got
buprenorphine legally. During those six months I took
care of my own treatment.
Eva’s experiences are similar to those of many others.
Several interviewees reported that it had taken more
than a year from the point where they applied for OST
until they actually began OST. In a number of cases a
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before the person was referred for assessment by the ad-
diction treatment services, in particular for those who
applied for treatment before 2010.
At the clinic, new patients are invited for an informa-
tion meeting where the treatment staff establishes
whether the criteria for OST are fulfilled or not. From
then on, ongoing contact is still required just to remain
on the waiting list. Overlooking a letter or missing an
appointment in some cases means losing the place on
the waiting list. Before treatment begins, the clinic often
demands detoxification, not infrequently, causing further
delays. Many interviewees characterized the assessment
process as one long obstacle course with unreasonable
demands.
The examples above all illustrate various difficulties in
gaining admission to OST. The interviewees describe
something akin to a Catch-22 situation. In order to gain
admission to OST, the applicant on the one hand has to
show zeal and have a sufficiently ordered life situation to
cope with a long and arduous assessment process. On
the other hand, the individual is required to prove that
he or she is a ‘hard-core addict,’ by providing docu-
mented negative consequences in the form of overdoses,
previous failed treatments, drug crimes, and needle
marks. Anyone with a hidden or insufficiently docu-
mented drug use runs a great risk of ending up outside
the system. This applies also for people with a very diffi-
cult and chaotic life situation, extensive polydrug use, or
mental health issues.
The examples in this section also illustrate the import-
ant roles that illicit methadone and buprenorphine may
play. People who do not ‘qualify’ or who give in along
the way can buy the substances on the street and man-
age their own treatment. For some, illicit medication
serves as a bridge into treatment by giving them the op-
portunity to stay motivated or give them sufficient har-
mony and structure in life to be able to cope with the
admission process.
Difficulties in remaining in OST
Admission to OST is no guarantee for continued treat-
ment. Patients not adhering to the rules of the programs
run the risk of being discharged. As mentioned in the
section about OST in Sweden, there are several official
‘just causes’ for an involuntary discharge [29]. According
to the national regulations, a discharge carry an auto-
matic 3-month suspension, during which the patient is
barred from re-applying for OST. In practice, however,
the waiting time is often considerably longer since wait-
ing lists for the programs are common.
Involuntary discharge was a reason cited by
several interviewees as to why they had started self-
medicating, either while they were waiting for re-admission to OST or because they no longer wanted
to remain in treatment. The most common discharge
reason was continued use of illicit drugs, which is well
in line with the results of previous Swedish research
[34]. Missed clinic appointments, disorderly or threat-
ening behavior, and drug crimes were also cited as
reasons.
One interviewee with vast experience of self-treatment
due to discharges is Sophie, a 53-year-old woman who at
the time of the interview had begun her seventh OST
episode. Sophie had been discharged six times, on
each occasion due to relapses into drug abuse, mainly
benzodiazepines. Several of the discharges had landed
Sophie in a difficult situation; the most recent discharge,
for instance, had resulted in her losing her housing pro-
vided by the social services.
The last three times Sophie was discharged, she
bought illicit methadone in order to continue treatment
on her own. It often took several months, in some cases
more than a year, before she was re-admitted to treat-
ment. Sophie characterized the discharges as if ‘they’d
cut me down at the knees’ and maintained that the illicit
methadone ‘had been her salvation’ during these periods.
Another example is Josef, a 29-year-old man whom we
encountered at the needle exchange. A few weeks earlier,
Josef had been discharged from treatment for the fourth
time. He was now using methadone or buprenorphine,
depending on what he was able to get hold of. He
explained that he had difficulties in keeping his place in
treatment, since he was seen as ‘disorderly’ and ‘trouble-
some’ by staff. ‘I’ve got ADHD, have difficulties control-
ling impulses, turning up on time, keeping appointments
and so on, treatment doesn’t work for me,’ he told us.
Josef was critical of the regulations and of the fact that
he had been involuntarily discharged several times. In
treatment, he felt powerless in relation to the staff, and
in his view there ought to be more flexibility and greater
consideration of his situation. ‘I feel you’ve got to have
certain rights even if you’re an addict in treatment,’ he
explained.
Another interviewee who pointed to strict regulations
and the demand to stay off drugs as the impetus for
turning to self-treatment is Anders, a 42-year-old man
who recently had been released from prison, after serv-
ing a lengthy sentence for drug-related crimes. Anders
had used heroin and cannabis regularly for more than
20 years and periodically also benzodiazepines, amphet-
amine, and cocaine. He used methadone and buprenor-
phine for self-medication purposes. At the time of the
interview, he had just been admitted to OST for the first
time, and he was about to start his methadone titration.
He had previously avoided seeking treatment because he
was convinced that he would be discharged quickly due
to his cannabis use.
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hashish more or less every day. I won’t give up this
habit, I don’t want to. I’ve been smoking since I was
12, and I need it to feel okay. I don’t smoke much, but
often a little every day. I’ll try telling them [treatment
staff] how it is, that I smoke some hashish, and that
I’ll test positive on the urine samples. We’ll see if they
go along with it. To my mind they need to put this in
it’s proper perspective. I mean, the important thing is
for me to quit the junk, and serious crime and stuff.
Then, for sure, it’s important not to do benzo or too
much alcohol when going on methadone, I know that,
that it’s dangerous to combine the substances. But to
smoke some weed isn’t dangerous and shouldn’t
prevent you from getting treatment. It’s not stopping
me from studying or working either, I was able to do
that before. If they can’t accept that I smoke, I’ll have
to go back to self-medicating.
Anders’ account reflects two different attitudes to
OST, attitudes that are reminiscent of what Ekendahl
[25] defines as a normalization and a harm reduction
discourse, respectively. On the one hand, Anders
stressed the importance of giving up heroin and crimin-
ality, which is in line with the normalization discourse.
He described smoking cannabis as legitimate, since he
saw that as self-medication, and it had not prevented
him from studying or working. On the other hand, he
highlighted the importance of reducing harm from and
negative consequences of drug use, rather than achieving
complete abstinence, which is more in line with the
harm reduction discourse.
The examples in this section show how a restrictive
treatment model, combined with regulations urging dis-
charges when rules are violated, both can lead to
repeated discharges and deter some people from seeking
treatment. This primarily seems to affect people who are
in a difficult situation already, such as concomitant men-
tal ill health or highly problematic drug use.Ambivalence or reluctance about entering OST
A number of interviewees admitted feeling ambivalent
about OST or reluctant to seek this treatment. One rea-
son for this could be that hitherto hidden drug use then
would be assessed and revealed. Some perceived it as
shameful having to seek help and as stigmatizing being
labeled an addict. Some also disagreed with the controls
and loss of autonomy which OST involves.Fear of being labeled or exposed as an addict
Several interviewees pointed out that their drug use to a
significant degree had been hidden from their nearest
and dearest, and that they did not see themselves as ‘realjunkies.’ Consequently, seeking treatment would be a
delicate, mortifying matter.
An example of this is Micke, a 31-year-old man who
had been in OST for about a month; but prior to that,
he had put off seeking help—treating himself in the
meantime—for more than a year. The main reason was
that he did not want to openly admit his addiction and
risk losing custody of his daughter.
The reason why I self-medicated the first time,
with buprenorphine, was that I didn’t want to seek
treatment. My addiction wasn’t known to many
people at the time, neither by my colleagues nor by
my family. Of course, I knew I needed treatment, and
that it would make life easier for me, but I didn’t want
to reveal my heroin addiction to the social services,
because I would then risk losing custody of my
daughter. That was a risk I wasn’t prepared to take.
Another example is Johan, a 27-year-old man, who
discussed the perils of revealing his dependence on
drugs but also his unwillingness to get in touch with the
authorities and running the risk of being labeled an ad-
dict. At the time of the interview, he was using illicit
methadone. He described how he had been self-
medicating for more than a year, and that it had helped
him quit heroin, improve his health, and that he had
managed to get a job. He saw great advantages with self-
treatment, since it enabled him to avoid contact with au-
thorities, and he did not have to tell his family or his
employer that he was a former heroin user. Most of all,
he was worried that revealing his background would lead
to him losing his driver’s license or his job.
So I like tried hiding it,’coz it was a bit humiliating,
you know, to tell mum and the rest about the heroin
[…] I’ve never really liked involving the authorities
and stuff, and get labeled. Most importantly because
of my job, I’ve got important endorsements on my
driver’s license and stuff.
Karin, a 32-year-old woman, also described it as nega-
tive having to be assessed and categorized as an addict.
For her, it was less the fear of any immediate conse-
quences and more about the feeling of shame and the
threat this posed to her own self-image. Karin had been
using analgesics, mainly morphine, for many years. She
characterized her drug use as self-medication and did
not see herself as a ‘real addict or junkie’. Karin had a
well-paid job, owned her own home, and told us that
she had not experienced any significant social problems
because of her drug use. At the time of the interview,
she was in OST but explained that she had put off seek-
ing help for several years, because she felt ashamed
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services.
Freedom from control measures and authority
Virtually, all the interviewees voiced the opinion that
OST subjects patients to control measures and authority,
and some even characterized the treatment as degrading.
In order to receive medication, you have to be in a cer-
tain place at a certain time, and nobody has an indisput-
able right to have time off. According to the regulations,
the medication is supposed to be taken under supervi-
sion at the clinic during the first 6 months. Patients are
not allowed to use other narcotic substances or to be
under the influence of alcohol when collecting medica-
tion. Furthermore, regular urine samples are taken under
supervision. Anyone who fails to adhere to the regula-
tions risks being sanctioned, which in the worst case
scenario means involuntary discharge. From this per-
spective, managing your own treatment can mean
greater autonomy and a sense of independence and self-
determination.
Self-treatment, however, is far from unproblematic.
The high cost of illicit medication and the limited access
to the substances were issues mentioned by several in-
terviewees. A number of the interviewees explained that
they had to pay several thousand Swedish kronor (hun-
dreds of euros) every month for their medicationd. It
was relatively common for them to go without medica-
tion for one or more days, due to difficulties in finding a
dealer, or because they were hard up. Difficulties in
keeping drug use ‘under control’ was another issue that
emerged in our interviews. Some interviewees told us
how they had experienced such difficulties in managing
their self-treatment that they, albeit very reluctantly, felt
compelled to seek OST.
Tim, a man in his 40s, told us how he had treated
himself with buprenorphine for many years. He ex-
plained how this previously had worked well, but that he
recently had begun to lose control. Difficulties in getting
medication and an accelerating polydrug use—heroin
and benzodiazepines among other substances—led to a
worsening social situation and several overdoses. Tim
had never been in OST before, but at the time of the
interview he had just applied for admission to a pro-
gram, since he felt he needed help to control his drug
use and straighten out his life. His justifications for self-
treatment and his thoughts about what had prompted
him to seek OST went as follows.
It’s about evading the control measures in there. You
know, having to give supervised urine samples and
that. Then they boss you around, telling you what you
can and can’t do. If you’re feeling rough one day and
you want to take a few benzos, you’re not allowed to.And then you have to go there every day for six
months to collect the medication. Then, if you
have been a good boy and kept to the straight and
narrow, you’re allowed to take the medication home.
But that’s just it, it’s these control measures that I
want to avoid. I’ve been thinking about seeking
treatment for ages, and I’ve come to the conclusion
that maybe now’s the time. I mean, I’m always
running around chasing [the substances]. You need it
[buprenorphine] every day, so why not … and these
control measures that we talked about earlier, but if
I’m a good boy and I want to do it, then the controls
aren’t that bad at the end of the day, not if it’s
voluntary on my part too, if I decide that now I’m
gonna take buprenorphine and stay on it, and try to
sort out my life, the social side of things, working or
studying.
Tim’s analysis indicates that treatment can be per-
ceived as controlling, intimidating, and disciplinary. Tim
really did not want to yield to the control measures but
still appeared to have realized that he needed help.
Moreover, he was tired of constantly chasing illicit medi-
cation. His analysis reflects a form of inner negotiation,
where he is trying to convince himself that the control
measures may not be that daunting after all.
One way of alleviating the negative experience of
powerlessness and subjection is to redefine the demands
on good conduct from a passive to an active position.
To be good, well mannered, and well behaved in order
to live up to the demands and expectations of the staff is
different from behaving properly on your own accord in
order to sort out one’s life and get a job. By redefining
the situation, Tim redresses the power balance, at least
intellectually. The perceived autonomy increases, and
the regulations appear less terrifying.
Other interviewees considered the loss of control that
treatment entailed too great a threat to their integrity.
Max is a 45-year-old man who had previously been in
treatment but had chosen to discontinue it due to nega-
tive experiences of control measures and disciplinary ac-
tions. In particular, he was critical of the travel
restrictions (imposed by the treatment system), since he
sometimes wanted to go abroad to see friends and family
and for work purposes. At the time of the interview, it
had gone 7 years since Max terminated his OST. From
then on, he had managed his own treatment, using illicit
methadone.
Max found great similarities between being a heroin
addict and being an OST patient. To some extent, the
patient is forced to associate with the same people (in
the waiting room at the clinic), and the patient is
dependent on a substance (medication instead of heroin)
and on treatment staff instead of dealers.
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You’re always forced to turn to a dealer or a pusher,
and in this case [the treatment staff of the program],
it’s a freaking nuisance of a pusher, who tells you, you
can’t smoke hashish, you can’t drop pills, you’ve got
to be on time, and you know … You see what I mean?
Max preferred methadone to heroin, but he also pre-
ferred the power of the ‘methadone pusher’ over the
power of the treatment system. According to him, man-
aging one’s own treatment is the best of three bad op-
tions. It emancipates the user from the compulsions of
life as a heroin addict—the constant money chasing,
interspersed with brief moments of satisfaction—while
also throwing off the shackles of the clinic, and its strict
rules and control measures.
I mean, from having been an addict, with all that stuff
completely controlling your life, that’s what you want
to avoid, right … so, the whole idea of being
ostensibly drug-free through medication, all that goes
up in smoke with all those rules, you know. That’s the
whole point, when you stop using drugs, you want
that freedom, you see. And they put a stopper to it
right away. […] The thing is, I can’t cope with it,
maybe it’s just me, but I can’t do it. The way I see it,
it’s like you’re giving up if you agree to those
conditions.
Seeking treatment is often seen as an important step
on the road to rehabilitation, getting a grip on life, to
break free from the dependence, and change one’s life
situation. The picture Max is painting is quite the
opposite. To enter OST is for him a sign of surrender in
the struggle for a life free from dependency and control
measures.
Discussion
Illegal use of OST medication—benefits and risks
Illicit use of methadone and buprenorphine has been
characterized as something negative and risky, both in
research and in the drug policy debate [5,8]. In Sweden,
an increase in methadone-related deaths in recent years
have been associated with diversion of medication from
OST programs. The expansion of OST and the new less
restrictive regulations have been identified as a purported
cause [35]. Critics of OST have also maintained that illicit
buprenorphine has become an increasingly common street
drug among young drug users [36].
Although illicit use of OST medication may carry
health, social, and legal implications, it is important to
present the complexity of the issue, both of the illicit use
itself, and of the forces driving the black market for
the substances.A current study indicates that diversion from Swedish
OST programs is a relatively common phenomenon
[33]. Another recent study, however, demonstrates that
illicit buprenorphine is used only very rarely by adoles-
cents and young adults whose drug use is not already
problematic [15]. The study indicates that the illicit use
of these substances primarily occurs among opioid-
dependent users outside OST, often for self-medication
purposes, which is in line with several other studies
[13,37-40].
Another study, which focused on the attitudes to and
views on diversion and illicit use among OST staff, also
gave a multifaceted picture of these phenomena [41]. Al-
though the staff saw diversion and illicit use as some-
thing negative and risky—the risk of fatalities through
overdosing if the substances reaches people with no opi-
oid tolerance, and the risk of diversion damaging the
legitimacy of treatment were factors stressed in particu-
lar—illicit use nonetheless was considered a better
option than using heroin. Staff members claimed that
nearly all patients who begun OST had some experience
of using the substances illicitly. Furthermore, patients
who had used them as a means of avoiding heroin often
were in a ‘better state’ than those patients who had
mainly used heroin [41].
The above mentioned studies all point to insufficient
access to OST as a partial explanation of the illicit mar-
ket for methadone and buprenorphine. This is some-
thing which also comes across in the accounts of our
interviewees. This study shows that illicit methadone
and buprenorphine are often seen as better alternatives
to heroin. These substances can give people with a
heroin dependence an opportunity to cut back on their
heroin consumption and improve their life situation.
They can also be used for long-term self-treatment—as
an alternative to OST, as a stepping stone to OST, and
as a way of handling waiting lists, or as a saving resource
in case of involuntary discharge.
The positive aspects of illicit use singled out here,
should not in any way be interpreted as diminishing the
issues and risks associated with such use; the substances
are used for other purposes than self-treatment, and in
riskier ways than those described by our select popula-
tion of very experienced drug users. For anyone lacking
tolerance for opiates, or with limited knowledge of
methadone and buprenorphine, these substances can be
lethal [42,43].
The results of our study reveal advantages with illicit
use of OST medication compared to heroin use, but also
that self-treatment may bring problems, not least in the
form of limited access to medication, and difficulties in
regulating the medication dosagee. One conclusion to be
drawn from this is that it is crucial to lower barriers to
OST, and to include more users with an opioid
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nerability, and potentially also reduce the demand for
OST medication on the illicit market.
Restrictive policies and negative attitudes to OST act as
barriers to treatment
OST can be seen as a discursive field where science and
values shape regulations, organization and practice
jointly [25,44]. As mentioned previously, the Swedish
OST model should be understood in light of the vehe-
ment ideological resistance which previously existed in
the country. For a long time, OST was seen as a last re-
sort, only to be offered to the hardest hit population of
heroin users [25,26]. The previous inclusion criteria with
mandatory documentation proving 4 years of intraven-
ous opioid abuse and several failed attempts at drug-free
treatment were direct results of this.
According to Swedish drug policy, solutions to drug
abuse are supposed to be firm, thorough, and abstinence
oriented [45,46]. For this reason, OST has been seen as
a measure which should aim at rehabilitation and
normalization, rather than harm reduction [25]. Abstin-
ence and normalization have always been vital goals of
the treatment and have legitimized a practice with
frequent, supervised urine samples [30]. Although treat-
ment has become less restrictive and more tolerant of
relapses in to drug use in recent years, the current treat-
ment policy still presents a number of barriers to OST.
Judging by the accounts of our interviewees, the
current inclusion criteria, long waiting times, and an
often arduous and bureaucratic admission process, in
conjunction with the preconception of professionals of
who belongs to the proper drug user category constitute
such barriers. Negative attitudes toward OST, fear of
stigmatization, and disciplinary actions raised further
barriers to seeking OST.
There are mainly three groups of opioid users who ap-
pear to be affected by these barriers. People dependent
on synthetic opioids, rather than opiates, do not fulfill
the inclusion criteria according to the current regulations.
People with a hidden and/or undocumented opioid de-
pendence encounter difficulties in qualifying for treatment
and often experience the assessment process (and previ-
ously, the mandatory contacts with the social services) as
intimidating or stigmatizing. Anyone with a chaotic or
precarious life situation—for instance users with severe
mental ill health and/or an extensive polydrug abuse—
often have difficulties in coping with an arduous admis-
sion process, as well as keep the mandatory daily appoint-
ments at the clinic and staying drug free.
There is previous research which indicate that restrict-
ive treatment regimes may severely limit access to treat-
ment [16-18], and that fear of stigmatization and
restrictions imposed on daily life act as barriers to OSTfor many drug users [19,47]. Patients’ concerns about
the ability to adhere to the treatment rules and ability to
remain in treatment have also been put forward as a rea-
son for not entering treatment [20].
The negative attitudes to OST displayed by our inter-
viewees are based on their own experiences, as well as
the views they have formed through the interaction
with other drug users. Previous research has also
shown how drug user’s attitudes to OST are influenced
by norms and values within ‘the addict subculture.’
This research indicates that the drug life on the street
is often seen as more active, independent, and exciting
than the neatly ordered and controlled life as a patient
in OST [48-50].
OST has been characterized as a treatment which
‘takes your heart out,’ and methadone patients are some-
times considered ‘losers’ by other drug users, since they
are no longer seen as being able to cope with the more
challenging and demanding life as a heroin user [49]. In
another study, methadone patients characterized their
situation in terms of stigmatization and a marginalized
identity—as patients, they were not considered ‘genuine
addicts’ anymore nor were they seen as ‘normal’ or drug
free [51].
Our interviewees painted a partly different picture.
Several interviewees explained that both ‘heroin life’ and
life in OST involve restrictions and voiced the opinion
that self-treatment offered greater autonomy and free-
dom—freedom from controls and restrictions of the
OST clinic but also freedom from the constant money
chasing of heroin life, and the precariousness which
often characterizes this type of lifestyle.
Harris and Rhodes [11] argue that a less restrictive
OST may have a liberating potential, if the patients are
given greater control over their own lives, and opportun-
ity to develop their own strategies to improve their
health and social situation. Rigid constraints and super-
vised consumption can cause as well as reduce harm,
they point out.
Some studies indicate that take-home doses achieve
better outcomes than inflexible dosing and/or supervised
consumption as regards retention rates, employment,
and improved quality of life [52,53]. These studies, fur-
thermore, suggest that take-home doses are not neces-
sarily leading to an increase in crime, illicit drug use, or
diversion.
Other studies, however, have pointed to control mea-
sures and supervision as having several important roles
to play. Control measures have been suggested as a
means of reducing illicit drug use among patients and
have been linked with a decreased mortality associated
with methadone diversion [9]. Control measures and
rules may also serve as a support for patients in their re-
habilitation process [54].
Richert and Johnson Harm Reduction Journal (2015) 12:12 Page 11 of 14An important challenge for OST is to strike the right
balance between control measures and freedom and
between high ambitions and reasonable demands and ex-
pectations. As objectives, rehabilitation and abstinence
can be positive, if they are realistic, designed in line with
the patient’s own wishes and abilities, and are not coupled
with sanctions. High ambitions may be beneficial for pa-
tients with good preconditions to live up to the demands
or are offered the necessary help to do so. However, high
demands and strict rules and inclusion criteria may also
mean that some patient populations are excluded from
OST or choose to manage treatment on their own.
Supervision and control measures are inevitable compo-
nents of OST, and they should primarily be prompted by
the objective of minimizing medical risks for the patients
and the risk of the substances being diverted to the black
market. It is important to find solutions that are both safe
and acceptable for the patients—to ensure that programs
expand access to and increase retention in treatment,
without endangering them or compromising quality [20].
Involuntary discharge: a questionable practice
Involuntary discharge from OST was a common motive
for self-treatment among our interviewees. Some of the
patients who had been involuntarily discharged described
the access to illicit medication as lifesaving. In two previ-
ous Swedish studies [34,55], the practice of involuntary
discharges has been characterized as dubious and inhu-
mane since it nearly always increases health risks and
bring about other negative consequences for anyone who
is discharged. Among other things, discharges have been
linked to a significantly increased mortality [56,57], and
the substances used in the treatment may cause strong
withdrawal symptoms if treatment is discontinued. Criti-
cism has been leveled at both the national regulations,
which cite a number of circumstances when discharges
should take place and the not infrequently arbitrary nature
of discharge decisions by staff [55].
Discharges pose a dilemma for OST. While discharges
in the majority of cases worsen the life situation for the
patient in question, there are also valid arguments for
having the option to discharge or at least reassign a
patient to another program. Patients who neglect or
mismanage their treatment not only put themselves at
risk, their conduct can also have a negative impact on
treatment practice and the legitimacy of treatment [41].
Patients who use benzodiazepines or alcohol while being
treated with methadone risk suffering an overdose.
Patients who systematically sell their medication to
people outside treatment put other people’s lives at risk
and may also besmirch the reputation of the treatment.
Patients who turn up at the clinic strongly intoxicated or
behave threateningly toward staff or fellow patients cre-
ate an unsafe and destructive treatment environment.The attitude to the overarching treatment aims is of
relevance when evaluating the practice of involuntary
discharges. There are, as already noted, two principal ap-
proaches. From a normalization perspective, with its
strong focus on rehabilitation and abstinence, discharges
can be legitimized on other grounds than the purely
medical; for instance, if the patient is not fulfilling his/her
commitments or is breaking the program rules [55]. From
a harm-reduction perspective, where the focus is on
reducing drug use and its negative consequences for the
individual, discharges are harder to justify since they
nearly always put the patient at greater risk than if he/she
were to remain in treatment.
The Swedish treatment model has traditionally been
based primarily on the normalization perspective,
although in recent years harm-reduction has gradually
grown in importance. Involuntarily discharges due to
transgressions have been common, also in cases where
the misconduct has not brought any clear medical risk
for the patient. Cannabis use, absence from treatment
for some time, as well as disorderly behavior are exam-
ples cited by our intervieweesf.
The opportunities for patients to express resistance
are limited. Hirchman’s [58] terms ‘exit’ and ‘voice’
throw light on two possible resistance strategies for dis-
satisfied service users. ‘Exit’ refers to the option of leav-
ing one service organization for another, while ‘voice’
means to speak up and protest. In Sweden, it is typically
not possible to switch programsg, and speaking up and
voicing criticism is, according to many patients, fraught
with perils [34]. This means that patients find them-
selves at a considerable disadvantage in relation to staff
[50,55]. The dependency on medication and the suspen-
sion rule exacerbate this disadvantage. For anyone
critical of the control measures or unable to live up to
the demands associated with regular treatment, self-
treatment with illicit medication may be the only avail-
able option.
Involuntary discharges are both ethically and medically
questionable. Discharges may be unavoidable under cer-
tain circumstances, but in our opinion this practice
ought to be applied extremely sparingly and only after
other reasonable measures have failed. A discharge
should not prevent anyone from quickly receiving a
place in another unit or operation. The suspension
period appears to be a Swedish phenomenon; there is no
scientific support for this practice, and it goes against re-
search findings which indicate the importance of high
retention and low thresholds to treatment [20].
Conclusion
The way OST is organized in Sweden means that many
people with an opioid dependence end up outside the
treatment system, despite the fact that they want to
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treatment on their own, using illicit methadone or
buprenorphine. For the majority of our interviewees,
self-treatment opened up an opportunity to cut down on
their heroin use and improve their life situation but was
also fraught with difficulties. An important objective,
therefore, ought to be to lower the barriers to OST.
Shorter waiting lists, more generous inclusion criteria,
and simplified admission processes could contribute to
this, as would fewer involuntary discharges, an abolished
suspension period, and a less paternalistic treatment
practice.
The high ambitions of the Swedish OST model, aimed
at normalization and abstinence, may be a force for good
if they are worked out in partnership with the patient
and if they are not leading to unreasonable demands and
an increased risk of involuntary discharges. Control
measures and regulations are necessary for the treat-
ment, but they should first and foremost be aimed at re-
ducing diversion and harmful drug use. Control
measures should be designed in such a way that they im-
pose as few restrictions as possible on the daily life
of patients and without appearing intimidating or
degrading.
Study limitations
The interviewees involved in this study constitute a se-
lect group of opioid users. All of them have encountered
various barriers to OST, and many have negative experi-
ences of OST. This means that they are decidedly more
critical toward OST than most other patients we have
interviewed in our project on diversion and illicit use of
methadone and buprenorphine. It should be pointed out
that many patients have positive experiences of OST and
do not find treatment degrading or stigmatizing.
The participants in this study are, furthermore, a par-
ticular population in terms of motives and experiences
of illicit use of methadone and buprenorphine. They all
have had the ambition to reduce their heroin use and
change their life situation and have primarily used the
substances for these purposes. There are also people
who use the substances in other riskier ways and for
other purposes than self-treatment.
The accounts of our interviewees are based on current
experiences as well as experiences that may be several
years old. Thus, some of these experiences reflect past
issues with the Swedish OST system, problems which
may be less prevalent today.
Endnotes
aPrior to admitting a patient, a social and medical as-
sessment is required, which involves several meetings.
Often, the person is required to go through detoxifica-
tion before the medication titration process commences.bFor many years in Sweden, prior contact with the so-
cial services was a mandatory requirement for anyone
applying for OST. During the period 2005–2009, this
was a requirement in the regulations. The formal re-
quirement was rescinded when the current regulations
(SOSFS 2009:27) came into force, but many OST pro-
grams still require the contact to be initiated through a
referral from the social services.
cMost of our interviewees use the medical product
name, Subutex or Suboxone, but in the quotes we have
altered this to the substance name throughout.
dThe average price of illicit methadone and buprenor-
phine varied depending on location (the study was con-
ducted in several towns and cities). For 90 mg of
methadone, the price varied between SEK 230 and SEK 360
(approximately EUR 25–40), for 8 mg of buprenorphine be-
tween SEK 110 and SEK 280 (approximately EUR 12–31),
and for 8 mg buprenorphine-naloxone between SEK 90
and SEK 250 (approximately EUR 10–27). The dosage used
in self-medication tended to be significantly lower than the
dosage used in official treatment programs, where the aver-
age 24-h doses are 100 mg methadone, 18 mg buprenor-
phine, and 19 mg buprenorphine-naloxone, respectively.
eThe way the interviewees managed their self-treatment,
how they got access to their medication, and the various
problems they experienced when self-treating will be dis-
cussed in greater detail in a future article.
fIt should be noted, however, that Swedish OST pro-
grams in general demonstrate relatively high retention
rates [59]. In all likelihood, this is associated with the fact
that strict inclusion criteria have created a select patient
population, and that Swedish programs have compara-
tively high dosage levels. Another factor may be that wait-
ing lists and suspension periods act as a deterrent for
some patients, making them more scrupulous about keep-
ing their places in treatment.
gHowever, a pilot project with free choice for OST is
being launched in one region.Competing interests
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